Longitudinal model-based meta-analysis in rheumatoid arthritis: An application toward model-based drug development

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 3, 2012, Pages 352-359

  Demin, I ^a   Hamren B ^a   Luttringer, O ^a   Pillai, G ^a   Jung, T ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Delenex Therapeutics AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CANAKINUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB;

ARTICLE; CLINICAL DEVELOPMENT PLAN; DECISION MAKING; DRUG APPROVAL; DRUG EFFICACY; HUMAN; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DECISION MAKING, ORGANIZATIONAL; DRUG DISCOVERY; DRUG EVALUATION; HUMANS; LONGITUDINAL STUDIES; META-ANALYSIS AS TOPIC; MODELS, THEORETICAL; TREATMENT OUTCOME;

EID: 84865438765     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.69     Document Type: Article

References (18)

1. Lalonde, R.L. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007). (Pubitemid 46950619)
2. Mandema, J.W., Gibbs, M., Boyd, R.A., Wada, D.R. & Pfster, M. Model-based meta-analysis for comparative efcacy and safety: application in drug development and beyond. Clin. Pharmacol. Ther. 90, 766-769 (2011).
3. van Vollenhoven, R.F. Treatment of rheumatoid arthritis: state of the art 2009. Nat. Rev. Rheumatol. 5, 531-541 (2009).
4. Stoll, J.G. & Yasothan, U. Rheumatoid arthritis market. Nat. Rev. Drug Discov. 8, 693-694 (2009).
5. Kukar, M., Petryna, O. & Efthimiou, P. Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. Biologics 3, 443-457 (2009).
6. Felson, D.T. et al. American College of Rheumatology. Preliminary defnition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727-735 (1995).
7. Mandema, J.W., Salinger, D.H., Baumgartner, S.W. & Gibbs, M.A. A dose-response meta-analysis for quantifying relative efcacy of biologics in rheumatoid arthritis. Clin. Pharmacol. Ther. 90, 828-835 (2011).
8. Ito, K., Ahadieh, S., Corrigan, B., French, J., Fullerton, T. & Tensfeldt, T.; Alzheimer's Disease Working Group. Disease progression meta-analysis model in Alzheimer's disease. Alzheimers. Dement. 6, 39-53 (2010).
9. Ahn, J.E. & French, J.L. Longitudinal aggregate data model-based meta-analysis with NONMEM: approaches to handling within treatment arm correlation. J. Pharmacokinet. Pharmacodyn. 37, 179-201 (2010).
10. McDevitt, H. et al. Infrastructure development for building, maintaining and modeling indication-specifc summary-level literature databases to support model-based drug development. PAGE Meeting 18, Abstr 1455 (2009).
11. Alten, R. et al. Efcacy and safety of the human anti-IL-1ß monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-fnding study. BMC Musculoskelet. Disord. 12, 153 (2011).
12. Schif, M. et al. Efcacy and safety of abatacept or infiximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 67, 1096-1103 (2008).
13. Furst, D.E. et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 30, 2563-2571 (2003). (Pubitemid 37549331)
14. Lunn, D.J., Thomas, A., Best, N., & Spiegelhalter, D. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat. Comput. 10, 325-337 (2000).
15. Gelman, A., Carlin, J.B., Stern, H.S., & Rubin, D.B. Bayesian Data Analysis. 2nd edn. (Chapman & Hall/CRC: Boca Raton, FL, 2003).
16. Kremer, J.M. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52, 2263-2271 (2005). (Pubitemid 41117408)
17. Keystone, E. et al. Certolizumab pegol plus methotrexate is signifcantly more efective than placebo plus methotrexate in active rheumatoid arthritis: fndings of a ffty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58, 3319-3329 (2008).
18. Alten, R. et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is efective in joint infammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res. Ther. 10, R67 (2008).